NCT01605032View on ClinicalTrials.gov

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Busulfan

Given IV

DRUG

Melphalan

Given IV

DRUG

Bortezomib

Given IV

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous PBSCT

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo autologous PBSCT

Trial Locations (4)

10016

NYU Cancer Institute, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

10461

Albert Einstein College of Medicine, The Bronx

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Albert Einstein College of Medicine

OTHER

NCT01605032 - Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter